Indicators on BCAT-IN-4 You Should Know
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze to evaluate various intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Primary demo aims were To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis suff